


## PHARMACEUTICAL 2018

## Dova Pharmaceuticals Inc. Rank 156 of 342





## PHARMACEUTICAL 2018

## Dova Pharmaceuticals Inc. Rank 156 of 342

The relative strengths and weaknesses of Dova Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dova Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Dova Pharmaceuticals Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 114%, being 69% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	96,317
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	35,197
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,000
Other Liabilities	0
Other Net Income	-746
Other Revenues	0
Property and Equipment	62
Research and Development	14,710
Selling, General and Administrative Expense	13,499

Output Variable	Value in 1000 USD
Assets	96,379
Liabilities	35,197
Expenses	29,209
Revenues	0
Stockholders Equity	61,182
Net Income	-29,955
Comprehensive Net Income	-29,955
Economic Capital Ratio	114%

